Charles River Laboratories Long Term Debt 2010-2025 | CRL
Charles River Laboratories long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.
- Charles River Laboratories long term debt for the quarter ending March 31, 2025 was $2.511B, a 5.63% decline year-over-year.
- Charles River Laboratories long term debt for 2024 was $2.24B, a 15.37% decline from 2023.
- Charles River Laboratories long term debt for 2023 was $2.647B, a 2.23% decline from 2022.
- Charles River Laboratories long term debt for 2022 was $2.708B, a 1.65% increase from 2021.
| Charles River Laboratories Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $2,240 |
| 2023 | $2,647 |
| 2022 | $2,708 |
| 2021 | $2,664 |
| 2020 | $1,930 |
| 2019 | $1,850 |
| 2018 | $1,637 |
| 2017 | $1,114 |
| 2016 | $1,208 |
| 2015 | $846 |
| 2014 | $741 |
| 2013 | $642 |
| 2012 | $527 |
| 2011 | $703 |
| 2010 | $670 |
| 2009 | $457 |
| Charles River Laboratories Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-03-31 | $2,511 |
| 2024-12-31 | $2,240 |
| 2024-09-30 | $2,327 |
| 2024-06-30 | $2,409 |
| 2024-03-31 | $2,660 |
| 2023-12-31 | $2,647 |
| 2023-09-30 | $2,514 |
| 2023-06-30 | $2,678 |
| 2023-03-31 | $2,744 |
| 2022-12-31 | $2,708 |
| 2022-09-30 | $2,937 |
| 2022-06-30 | $2,997 |
| 2022-03-31 | $2,676 |
| 2021-12-31 | $2,664 |
| 2021-09-30 | $2,893 |
| 2021-06-30 | $2,727 |
| 2021-03-31 | $2,202 |
| 2020-12-31 | $1,930 |
| 2020-09-30 | $1,968 |
| 2020-06-30 | $2,207 |
| 2020-03-31 | $2,327 |
| 2019-12-31 | $1,850 |
| 2019-09-30 | $1,883 |
| 2019-06-30 | $2,040 |
| 2019-03-31 | $1,541 |
| 2018-12-31 | $1,637 |
| 2018-09-30 | $1,653 |
| 2018-06-30 | $1,796 |
| 2018-03-31 | $1,130 |
| 2017-12-31 | $1,114 |
| 2017-09-30 | $1,156 |
| 2017-06-30 | $1,116 |
| 2017-03-31 | $1,170 |
| 2016-12-31 | $1,208 |
| 2016-09-30 | $1,233 |
| 2016-06-30 | $1,331 |
| 2016-03-31 | $840 |
| 2015-12-31 | $846 |
| 2015-09-30 | $836 |
| 2015-06-30 | $755 |
| 2015-03-31 | $755 |
| 2014-12-31 | $741 |
| 2014-09-30 | $755 |
| 2014-06-30 | $782 |
| 2014-03-31 | $614 |
| 2013-12-31 | $642 |
| 2013-09-30 | $624 |
| 2013-06-30 | $620 |
| 2013-03-31 | $518 |
| 2012-12-31 | $527 |
| 2012-09-30 | $543 |
| 2012-06-30 | $551 |
| 2012-03-31 | $675 |
| 2011-12-31 | $703 |
| 2011-09-30 | $720 |
| 2011-06-30 | $731 |
| 2011-03-31 | $761 |
| 2010-12-31 | $670 |
| 2010-09-30 | $701 |
| 2010-06-30 | $409 |
| 2010-03-31 | $438 |
| 2009-12-31 | $457 |
| 2009-09-30 | $464 |
| 2009-06-30 | $486 |
| 2009-03-31 | $474 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $7.829B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $146.605B | 27.50 |
| CVS Health (CVS) | United States | $81.948B | 10.19 |
| Elevance Health (ELV) | United States | $76.969B | 9.93 |
| Cencora (COR) | United States | $57.219B | 19.91 |
| DiDi Global (DIDIY) | China | $24.191B | 25.70 |
| Natera (NTRA) | United States | $21.906B | 0.00 |
| Labcorp Holdings (LH) | United States | $20.893B | 16.95 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.687B | 0.00 |
| CochLear (CHEOY) | Australia | $12.827B | 0.00 |
| Solventum (SOLV) | United States | $12.768B | 13.52 |
| ICON (ICLR) | Ireland | $12.156B | 11.30 |
| Revvity (RVTY) | United States | $11.964B | 20.59 |
| Viatris (VTRS) | United States | $10.704B | 3.68 |
| Medpace Holdings (MEDP) | United States | $9.298B | 24.69 |
| Avantor (AVTR) | United States | $9.254B | 13.45 |
| Sonic Healthcare (SKHHY) | Australia | $8.886B | 0.00 |
| HealthEquity (HQY) | United States | $8.174B | 35.80 |
| Caris Life Sciences,�Inc (CAI) | United States | $6.744B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.911B | 28.92 |
| BrightSpring Health Services (BTSG) | United States | $3.571B | 32.76 |
| Sotera Health (SHC) | United States | $3.349B | 19.03 |
| Surgery Partners (SGRY) | United States | $2.825B | 36.73 |
| Alignment Healthcare (ALHC) | United States | $2.645B | 0.00 |
| Organon (OGN) | United States | $2.584B | 2.75 |
| Concentras Parent (CON) | United States | $2.551B | 14.74 |
| GeneDx Holdings (WGS) | United States | $2.356B | 90.72 |
| Ardent Health (ARDT) | United States | $2.027B | 8.64 |
| Progyny (PGNY) | United States | $1.990B | 43.79 |
| PACS (PACS) | United States | $1.932B | 0.00 |
| Premier (PINC) | United States | $1.736B | 13.18 |
| GoodRx Holdings (GDRX) | United States | $1.695B | 33.89 |
| Teladoc Health (TDOC) | United States | $1.460B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.298B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.127B | 8.58 |
| CareDx (CDNA) | United States | $1.121B | 17.50 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| Agilon Health (AGL) | United States | $0.923B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.848B | 291.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.810B | 7.58 |
| Nutex Health (NUTX) | United States | $0.637B | 9.64 |
| Embecta (EMBC) | United States | $0.612B | 4.12 |
| InnovAge Holding (INNV) | United States | $0.559B | 0.00 |
| SBC Medicals (SBC) | United States | $0.523B | 0.00 |
| LifeMD (LFMD) | United States | $0.512B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.482B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.471B | 10.60 |
| Omada Health (OMDA) | $0.455B | 0.00 | |
| So-Young (SY) | China | $0.390B | 0.00 |
| Enhabit (EHAB) | United States | $0.357B | 29.38 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.344B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.321B | 0.00 |
| Oncology Institute (TOI) | United States | $0.279B | 0.00 |
| Beauty Health (SKIN) | United States | $0.241B | 0.00 |
| DocGo (DCGO) | United States | $0.152B | 24.83 |
| Pheton Holdings (PTHL) | China | $0.138B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.107B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.079B | 0.00 |
| KindlyMD (NAKA) | United States | $0.074B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.061B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| ModivCare (MODV) | United States | $0.046B | 0.00 |
| Biodesix (BDSX) | United States | $0.045B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.042B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.023B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.009B | 0.00 | |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.007B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |